Memocit

Patient Information Leaflet

Memocit, 1000 mg/10 ml, oral solution
Citicolinum
Please read all of this leaflet carefully before taking this medicine, because it contains
important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please ask your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm other people, even if their symptoms are the same.
• If you experience any side effects, including any not listed in this leaflet, please inform your doctor or pharmacist. See section 4.

Table of contents

1. What Memocit is and what it is used for
2. Important information before taking Memocit
3. How to take Memocit
4. Possible side effects
5. How to store Memocit
6. Contents of the pack and other information

1. What Memocit is and what it is used for

Memocit contains citicoline as the active substance, which belongs to a group of medicines called
psychostimulants and nootropics (so-called "cognitive enhancers"). These medicines work by
improving brain function.
Memocit is used in the treatment of neurological and cognitive disorders caused by:

• Interruption of blood supply to the brain due to blood clot formation or damage to cerebral blood vessels (e.g. stroke);
• Head injuries (e.g. resulting from impact).

2. Information before using Memocit

When not to use Memocit

• if the patient is allergic to citicoline or any of the other ingredients of this medicine (listed in section 6);
• if the patient has increased sympathetic nervous system activity, a serious condition characterized by low blood pressure, excessive sweating, rapid heartbeat, and fainting.

Warnings and precautions
Before starting treatment with Memocit, discuss with your doctor:

• if the patient is allergic to acetylsalicylic acid, as this medicine may cause asthma attacks.

Children
There is insufficient data on the use of Memocit in children; therefore, this medicine should only be administered if the doctor decides it is necessary.

Memocit with other medicines
Inform your doctor about all medicines the patient is currently taking or has recently taken,
as well as any medicines the patient plans to take.
Citicoline enhances the effects of L-dopa (also known as levodopa, used in the treatment of Parkinson's disease); therefore, concomitant use of these medicines must be decided exclusively by a doctor.
Concomitant use of citicoline with meclofenoxate (a central nervous system stimulant) is not recommended.

Taking Memocit with food and drink
Memocit may be taken on an empty stomach or with food.

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor before using this medicine.

Driving and operating machinery
Memocit has no influence on the ability to drive or operate machinery.

Memocit contains liquid, non-crystallizing sorbitol (E 420)
Sorbitol is a source of fructose. If the patient (or their child) has previously been diagnosed with intolerance to certain sugars or hereditary fructose intolerance—a rare genetic disorder in which the patient's body cannot break down fructose—the patient should consult a doctor before taking this medicine or giving it to a child.
If the patient has previously been diagnosed with intolerance to certain sugars, the patient should consult a doctor before taking this medicine.

Memocit contains propyl parahydroxybenzoate (E 216), methyl parahydroxybenzoate (E 218), and carmine (E 124).
This medicine may cause allergic reactions (including delayed-type reactions).

Memocit contains 77 mg of sodium (the main component of table salt) per sachet.
This corresponds to 3.85% of the maximum recommended daily dietary intake of sodium for adults.

3. How to take Memocit

This medicine should always be taken exactly as directed by your doctor. In case of doubt, consult
your doctor or pharmacist.
The recommended dose for adults is 1 to 2 sachets per day, depending on the severity of the disease symptoms.
This medicine may be taken directly from the sachet or after dissolving in half a glass of water
(approximately 120 ml), during or between meals.

1. Hold the 2. With the other hand 3. The medicine can be 4. After dissolving Memocit 1000 mg sachet along the tear line indicated by arrows, open the sachet and shake well. taken directly or dissolved in half a glass of water (120 ml).

Taking more Memocit than prescribed
If you take more than the prescribed dose of this medicine, contact your doctor immediately.
Take the medicine package or this leaflet with you so that medical personnel know which medicine has been taken.
Missing a dose of Memocit
Take the missed dose as soon as possible.
Do not take a double dose to make up for a missed dose.
Stopping treatment with Memocit
Your doctor will determine how long you should take Memocit. Do not stop taking this medicine without consulting your doctor.
If you have any further questions about the use of this medicine, consult your doctor.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everybody will experience them.
Adverse reactions occurring very rarely (less frequently than in 1 out of 10,000 people):

• hallucinations,
• headaches, dizziness,
• changes in blood pressure (increased or decreased blood pressure),
• breathing difficulties (dyspnoea),
• nausea, vomiting, diarrhoea,
• redness, urticaria, rash, purpura,
• oedema,
• chills.

Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed
in this leaflet, inform your doctor or pharmacist. Adverse reactions can
be reported directly to the Department of Monitoring Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
By reporting adverse reactions, additional information regarding the safety of the medicine can be collected.

5. How to store Memocit

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and sachet.
The expiry date refers to the last day of the stated month.
The label on the packaging shows the expiry date after the abbreviation EXP, and the batch number after the abbreviation LOT/Lot.
No special storage conditions are required for this medicine.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. Such measures help protect the environment.

6. Contents of the pack and other information

What Memocit contains

• The active substance in Memocit is citicoline. Each millilitre of solution contains 100 mg citicoline (as the sodium salt). Each sachet (10 ml solution) contains 1000 mg citicoline (as the sodium salt).
• Other ingredients are: sorbitol liquid, non-crystallizing (E 420), glycerol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), potassium sorbate, sodium saccharin, glycerol formal, carmine red (E 124), citric acid, sodium citrate, strawberry flavour (containing propylene glycol (E 1520), flavouring substances), purified water.

What Memocit looks like and contents of the pack
Memocit is a clear, pink oral solution with a strawberry taste and odour.
The medicine is packed in sachets made of PET/white extruded PE/aluminium/extruded copolymer, each containing 10 ml of solution, placed in a cardboard box.
The pack contains 10 sachets of 10 ml solution.

Marketing Authorisation Holder
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
tel. + 48 22 364 61 01

Manufacturer
SAG Manufacturing S.L.U.
Crta N-I, Km 36
San Agustin de Guadalix
28750 Madrid
Spain

Galenicum Health, S.L.U.
Sant Gabriel, 50
Esplugues de Llobregat
08950 Barcelona
Spain